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Abstract
Background: Interstitial lung diseases in children (chILD) are rare and consist of many different entities that affect
the parenchyma of the lungs, leading to a chronic lung disease. The natural course of many of these diseases is
connected with a high morbidity and significant mortality. Symptomatic treatment consists of oxygen
supplementation, adequate nutrition adapted to the high energy demand generated by the disease due to the
increased breathing effort required, as well as immunization against respiratory pathogens to prevent exacerbations
through respiratory infections. No proven pharmacological treatments are available to date. This placebo-controlled
study aims to evaluate the efficacy and safety of the mid-term use of hydroxychloroquine in chILD.
Methods and design: The study is an explorative, prospective, randomized, double-blind, placebo-controlled
investigation of hydroxychloroquine (HCQ) in chILD. Patients can be included into the trial when diagnosed with a
chronic (≥ 3 weeks’ duration) diffuse parenchymal lung disease (chILD) (1) genetically defined, (2) histologically
defined or (3) diagnosed with idiopathic pulmonary hemorrhage (hemosiderosis). The study contains of two
different study blocks, a START and a STOP block, which can be initiated in any sequence. Each patient can
participate in each block only once. In the START block subjects are randomized to parallel groups for 4 weeks
treatment, then the placebo group is switched to the active drug. In the STOP block, subjects taking HCQ are
randomized into parallel groups treated with placebo or HCQ.
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Discussion: This study is the first international, investigator-initiated, prospective and controlled investigation of a
pharmacological treatment in chILD. The block design was selected as it has the advantage of accommodating
patients who are initiating or withdrawing from HCQ therapy, thus allowing the participation of those who were
previously started on off-label HCQ. The cross-over design and selected outcome parameters enables us to include
appropriate numbers of patients of all age groups from neonates to adults suffering from these rare diseases.
Trial registration: This is an exploratory, Phase 2a, randomized, double-blind, placebo-controlled, parallel-group,
multinational study investigating the initiation or withdrawal of hydroxychloroquine in subjects with chILD. Study
title: Hydroxychloroquine in pediatric ILD: START randomized controlled in parallel groups, then switch placebo to
the active drug, and STOP randomized controlled in parallel groups to evaluate the efficacy and safety of
hydroxychloroquine (HCQ). Short title: HCQ in pediatric ILD, particularly 4surfdefect. EudraCT, ID: 2013–003714-40.
Registered on 2 July 2013. ClinicalTrials.gov, ID: NCT02615938. Registered on 8 November 2015. IZKS trial code:
2013–006; Sponsor: University Hospital, Ludwig-Maximilians University of Munich. Responsible Party: Prof. Dr. med.
Matthias Griese, University Hospital, Ludwig-Maximilians University of Munich, Germany.
Keywords: chILD, Interstitial lung disease, Hydroxychloroquine
Background
Interstitial lung disease in children (chILD) is an umbrella
term for more than 200 different entities that affect the
parenchyma of the lungs, leading to a chronic lung
disease. Previous studies have reported an incidence of
0.1–16 per 100,000 children per year and a prevalence of
1.3–3.6 per million children [1–3]. Often the children are
dependent on oxygen (O2) for a long period of time or re-
quire mechanical ventilation [4]. The overall mortality in
childhood is around 15% [4]. No successfully proven treat-
ments are available and there only exist few pharmaco-
logical treatment options based on expert agreement [5]
and anecdotal experience collected from individual treat-
ments. Symptomatic treatment consists of O2 supplemen-
tation if necessary, adequate nutrition adapted to the high
energy demand generated by the disease due to the in-
creased breathing effort required, as well as immunization
against respiratory pathogens to prevent exacerbations
through respiratory infections [6]. Common drug treat-
ments include glucocorticosteroids, hydroxychloroquine
(HCQ), and steroid-sparing agents, such as azathioprine,
cyclophosphamide, cyclosporine or methotrexate, are also
tried [6]. A few cases with possible responses to macrolide
antibiotics have been reported.
Due to the rarity of the diseases, only international
studies can collect sufficient numbers of patients to
evaluate treatment in controlled settings. We used the
European-wide project on chILD, the chILD-EU project
[7], to prepare and implement a randomized controlled,
Phase 2a study to evaluate treatment with HCQ in
chILD. With this study we aim to: (1) evaluate the effi-
cacy of HCQ against placebo in chILD, (2) evaluate the
safety of the mid-term use of HCQ, (3) be able to make
a decision on the risks and benefits of the use of HCQ
and (4) help in standardizing the pharmacological treat-
ment of chILD.
HCQ is approved for the treatment of malaria, rheuma-
toid arthritis, juvenile idiopathic arthritis, lupus erythema-
tosus and dermatological conditions caused or aggravated
by sunlight [8]. Due to the assumed various immunomod-
ulatory mechanisms of HCQ it has been used frequently
for more than 40 years off-label for different autoimmune
diseases (e.g., Sjögren’s syndrome and inflammatory osteo-
arthritis) in a wide range of clinical conditions and, in par-
ticular, in chronic or acute and often very severe pediatric
diffuse parenchymal lung diseases.
Eighty-three cases of chILD were reported between
1984 and 2013 to have been treated with chloroquine
(CQ) or HCQ alone or in combination with other drugs
[9]. From these data it was not possible to predict which
patients would benefit from the treatment. Clear positive
clinical improvements, usually occurring within 4 weeks,
have been reported in 15 of 16 published cases when
HCQ was given alone, and in 37 of 53 published cases,
when given in combination with glucocorticosteroids.
Obviously, a publication bias towards successful cases
has to be considered.
Applications even for many years appeared safe with
very few reported side effects during off-label usage [9].
Again, a significant underreporting of side effects or un-
successful trials has to be expected. The oral doses
ranged from 3.5–10mg/kg bodyweight per day [9]. In
this respect it is notable that there exist two pharma-
ceutical forms of HCQ, HCQ base and the HCQ sulfate
(correction factor 200 mg sulfate = 155 mg base) [9]. The
majority of case reports and small series did not indicate
which of the two pharmaceutical forms the dose is refer-
ring to. Hydroxychloroquine treatment may have several
side effects including rare retinal changes and, most fre-
quently, abdominal discomfort and pain. The retinal
changes are dose-dependent and can be irreversible [10].
In one series of patients who received HCQ, abdominal
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pain in the first week of treatment was reported in a mi-
nority of cases [11].
The use of HCQ in a trial in chILD has several important
challenges. Firstly, it is used in a broad age and weight range,
from birth to adulthood, with not much pharmacological
data available [9]. Secondly, disease severity varies from acute
respiratory distress and failure to thrive to chronic, mild par-
tial respiratory insufficiency. Randomization of acutely ill pa-
tients to treatments which may potentially be harmful may
be very difficult to achieve and consent by the caregivers,
even if the treatments might be helpful, may not be given,
thus reducing the number of subjects that can be included.
Nevertheless, patients in a chronic disease state have a differ-
ent response pattern than those who are acutely sick. All this
must be addressed by an appropriate study design. Thirdly,
no randomized controlled studies have been performed in
chILD. Therefore, outcome variables have not been used in
studies and their responsiveness to treatments is unknown.
Lastly, the extreme rarity and heterogeneity of the diseases
targeted, as well as their wide geographical scattering, in-
duces significant burden and huge logistic challenges for
such a clinical trial. The goal of this Phase 2a study is to in-
clude all chILD patients who are planned to be, or are ac-
tively being, treated with HCQ. We intend to gather as
much information as possible to improve the knowledge in
this group of patients. Therefore, the character of this study
is explorative and not confirmatory. It was designed to
closely accommodate the current clinical care situation.
Methods and design
Study goals, duration and number of subjects planned
This study is an explorative, prospective, randomized,
double-blind, placebo-controlled, investigator-initiated
investigation of HCQ in pediatric ILD. We aim to: (1)
evaluate the efficacy of HCQ against placebo in chILD,
(2) assess the safety of the mid-term use of HCQ, (3) be
able to make a decision on the risks and benefits of the
use of HCQ and (4) help in standardizing the pharmaco-
logical treatment of chILD. Subject recruitment started
in August 2015 and was expected to be low because the
numbers of eligible patients were unknown. At the be-
ginning of the study we planned to assess over 100 sub-
jects for eligibility and to allocate 80 subjects to each
study block. Recruitment and treatment of subjects was
expected to be performed in up to 100 trial centers. The
estimated study completion date is April 2025.
The cross-over design
To include as many possibly eligible patients in the
study, the study contains two different study blocks, a
START block and a STOP block. These may be initiated
in any sequence by the subjects. By this method, patients
already taking HCQ for various time periods and with
unknown drug-related benefits may also be recruited to
the study. Each patient can complete each block only
once. In the START block, subjects are randomized to
parallel groups for 4 weeks, then the placebo group is
switched to the active drug for another 4 weeks. In the
STOP block, subjects taking HCQ are randomized into
parallel groups treated with placebo or HCQ for 3
months to investigate the withdrawal of HCQ for assess-
ment of its efficacy and then followed for another 3
months (Fig. 1 and Additional file 1). We expect an
equal distribution between the START and STOP blocks
as, optimally, each patient progresses through both study
blocks.
Schedule of the study
At the beginning and at the end of a treatment block the
participants must consult an ophthalmologist to assess
any disturbance of central vision, check their visual and
reading acuity, and undergo a slit-lamp examination and
fundoscopy. Only at the discretion of the ophthalmolo-
gist may ocular coherence tomography (OCT), fundus
auto-fluorescence (FAF) imaging, stereoscopic slit-lamp
examination of the retina (e.g., with a 90-D or 78-D bi-
convex lens), and central visual field examination using
an Amsler chart (preferably red on black) or automated
perimetry be performed. Evaluation may need to be ex-
tended according to signs and symptoms to include ret-
inal photography and visual electrophysiological tests.
For patients who have previously received continuous
treatment for more than 5 years, an individual arrange-
ment should be agreed with the ophthalmologist. Visual
side effects are dose-related and the drug should be
stopped, if they develop.
At baseline and end of the trial, as well as after 4
weeks (START block) and 12 weeks (STOP block), the
participant should undergo electrocardiography testing.
Any signs of conduction disorders (bundle-branch
block/atrio-ventricular heart block) as well as biventricu-
lar hypertrophy can be a sign of cardiomyopathy, which
has been described as occurring while receiving HCQ. In
this case, further cardiological workup is necessary. If
there are any signs or symptoms of cardiomyopathy,
HCQ must be discontinued immediately. The echocardi-
ography is performed to assess for pulmonary hyperten-
sion and to exclude cardiomyopathy at the beginning of
the study. Any signs of hypoglycemia, like low blood glu-
cose levels or reports of potential hypoglycemic episodes,
will lead to intensive observation of blood glucose levels
and, if persistent, change of medication (e.g., reduction
or stopping).
Outcome parameters
There are not yet any validated outcome parameters
available for a patient’s respiratory condition in chILD.
We selected as the primary outcome parameter the
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change in oxygenation. If no supplemental O2 is ne-
cessary the O2 saturation is measured twice over 1
min in an awake patient after 5 min at rest. The mea-
surements have to be at least 1 min apart. The stable
average value will be recorded. If the patient needs
supplement O2, the supplementation is withdrawn
after 5 min at rest and the O2 saturation is measured
twice over 1 min. The measurements have to be at
least 1 min apart. The stable average value will be re-
corded. If the O2 saturation falls below SpO2 80%, O2
is returned to the patient and and the value of 80% is
recorded. The patient’s respiratory condition can vary
considerably over relatively short time periods from
breathing room air to being ventilated. Therefore,
oxygenation cannot be determined from O2 saturation
alone, but we also need to consider the respiratory ef-
fort of the subject or support needed as necessary to
achieve a certain O2 saturation. The patient is defined
as a responder to the initiation or to the withdrawal
of HCQ if the O2 saturation, respiratory rate, O2
airflow or the oxygenation index change to a clinically
meaningful extent (Table 1). We did not include pO2
or pCO2 alone in the primary outcome to assess oxy-
genation because these variables very rapidly change
in infants and children with crying or in different ac-
tivity circumstances.
For secondary outcome parameters the following vari-
ables will also be investigated:
 Clinical responses: intercostal retraction, coughing,
weight for height, clinical course of lung disease
(since last visit), number of pulmonary
exacerbations, and changes in chest x-ray as well as
changes in pulmonary function tests and distance of
the 6-min walking test (if the child is old enough to
perform the tests)
 Change in co-medication: cumulative amounts of
steroid equivalents
 Patient-reported outcome (self-assessment
questionnaires): quality of life and health economics
a
b
Fig. 1 Schematic study setup. The study contains two different study blocks: a START block (a) and a STOP block (b) These blocks can be initiated
in any sequence as needed by the subjects. Each patient can participate in each block only once
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All analyses of secondary outcome will be interpreted
purely exploratorily.
Safety monitoring
Safety monitoring for the drug is performed noting ad-
verse events (AEs), clinical laboratory values (differential
blood count glutamic oxaloacetic transaminase (GOT),
glutamate-pyruvate transaminase (GPT), gamma gluta-
myl transpeptidase (gGT), creatinine, lactate dehydro-
genase (LDH), potassium, creatine kinase, blood glucose
levels, HCQ steady-state drug level), electrocardiog-
raphy, echocardiography and ophthalmological review.
Inclusion and exclusion criteria
Patients can be included into the trial when diagnosed
with a chronic (≥ 3 weeks’ duration) diffuse parenchymal
lung disease (chILD) that is: (1) genetically defined (e.g.,
surfactant protein B/C (SFTPC, SFTPB), ATP-binding
cassette transporter 3 (ABCA3), NK2 Homeobox 1
(NKX2–1), T-box transcription factor 4 (TBX4), Nie-
mann-Pick disease B/C (NPC2, NPC1, NPB), coatomer
subunit alpha (COPA), lipopolysaccharide-responsive
and beige-like anchor protein (LRBA) or others), (2)
histologically defined (e.g., chronic pneumonitis of in-
fancy, desquamative interstitial pneumonia, lipoid pneu-
monitis, cholesterol pneumonia, non-specific interstitial
pneumonia, pulmonary alveolar proteinosis (after the ex-
clusion of mutations in granulocyte-macrophage colony-
stimulating factor-receptor (GMCSF-R)a/b and GMCSF
autoantibodies), usual interstitial pneumonia, follicular
bronchitis/bronchiolitis, lymphogenic interstitial pneu-
monia, storage disease with primary pulmonary involve-
ment) or (3) diagnosed with idiopathic pulmonary
hemorrhage (hemosiderosis). Patients have to be clinic-
ally stable with no major changes in their medication
(Table 2). Exclusion criteria for patients are listed in
Table 3. In an amendment, the following entities were
removed to restrict the spectrum of the cohort: micro-
vasculopathy, cryptogenic organizing pneumonia, diffuse
alveolar damage/acute interstitial pneumonia, acute fi-
brinous and organizing pneumonia, giant-cell pneumo-
nia, chILD clinically diagnosed (CDB-ILD), respiratory
bronchiolitis-interstitial lung disease, sarcoidosis, hyper-
sensitive pneumonitis, neuroendocrine-cell hyperplasia
of infancy and pulmonary interstitial glycogenosis.
Randomization and blinding
Patients are allocated to the two treatments, orally admin-
istered HCQ and placebo, in a ratio of 1:1 by central
randomization within each age group. The age-matched
stratification is performed according to two age groups
defined as: (1) infants aged between 3 weeks and 2 years
of age and (2) children aged older than 2 years. As of an
anticipated skewed frequency distribution of cases, the
older ones being less frequent. The randomization proced-
ure does not consider the sex of the patients, since no sex-
specific responses to HCQ therapy have been reported yet
and are not expected. The randomization list is generated
by an independent institute using a validated system,
which involves a pseudo-random number generator to en-
sure that the resulting treatment sequence will be both re-
producible and non-predictable.
The study medication is packed and blinded according
to the random list. Each patient medication box is sent to-
gether with the sealed emergency unblinding envelopes to
the sites. At the end of the trial, any emergency opening
of the envelopes will be controlled after collecting the ex-
planations for unblinding and checking the unused treat-
ment units. The code, which is kept confidential in the
pharmacy, will be broken regularly only at the end of the
study, and after checking the data, recording any protocol
violations after freezing the statistics database, allowing
the collected data to be analyzed.
Blinding was achieved by providing the study-specific
HCQ powder/substance and placebo-powder/substance
in appropriately covered capsules to keep the contents
invisible for both of the study drugs, HCQ and placebo.
Placebo capsules contain sucrose octaacetate to obscure
the bitter taste of HCQ. In a double-blinded testing,
eight healthy volunteers were not able to distinguish pla-
cebo from HCQ.
The dose
Commonly in chILD, the HCQ sulphate is given at a
dose of 10 mg/kg bodyweight per day. After extensive
discussion with the lead competent authority (the Ger-
man BfArM) and a European group of chILD experts,
on the basis of safety data available, and extensive ex-
perience in pediatric rheumatology, the dose was set at
10 mg/kg bodyweight per day for loading during the ini-
tial week of treatment, followed by 6.5 mg/kg body-
weight per day. In the STOP block, the individual dose
that a patient has been taking until enrollment should
be continued. The selected duration of the placebo
phase was the result of a delphi questionnaire among
European pediatric pneumologists and balanced the an-
ticipated time point, when a treatment effect could be
noted in a majority of patients if present, and the time
period tolerated to withhold the drug from a placebo-
treated subject [9].
The risks
The clinical research interventions and procedures
planned represent an appropriate balance of risk and
potential benefit. Specific measures were implemented
to ensure adequate protection for minors, including
parental permission and assent of able children, assur-
ance of a direct benefit for the child and minimization
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of the overall risk of study participation. The risks to
which the children are exposed are low, both compared
to the potential therapeutic benefits and the risks of the
disease. The additional burden put on the children
from participation in the study is minimal. Except for a
sample for HCQ blood-level measurements, no investi-
gations or tests are performed, which would not be
performed outside the study setting, including ophthal-
mological and cardiological investigations, as well as
liver function tests.
The statistical analysis
Due to the exploratory nature of the study there is
no formal sample size calculation. The study aims to
include as many patients as possible in both START
and STOP blocks (optimally 80 patients in each or up
to 160 participants in one block only). At least over
100 patients should be included in the study. All ran-
domized subjects are included in the intention-to-
treat (ITT) population. This population is the primary
analysis population. Within the ITT population ana-
lyses, subjects will be assigned to the treatment to
which they were randomized. For the combined ana-
lysis, the ITT population consists of all patients who
are at least in the START or the STOP block. For
analysis, subgroups of patients will be defined, based
on age, categories of diagnosis and further appropri-
ate factors. The statistical final analysis plan (SAP)
will be documented before unblinding of group
allocation.
Efficacy analyses
The primary populations for the analyses of efficacy are
the ITT populations (randomized patients) for each
block. For the combined analysis the ITT population
consists of all patients who are at least in the START or
the STOP block. For all hypotheses, two-sided explora-
tory p values will be provided. If appropriate, the ana-
lyses will be adjusted for the stratification factor of the
randomization (age group).
Analysis of adverse events
All summaries and listings of safety data are performed
for the safety population. Frequencies of subjects experi-
encing at least one adverse event (AE) are displayed by
body system and preferred term according to Medical
Dictionary for Regulatory Activities (MedDRA) termin-
ology. Detailed information collected for each AE will
include the description of the event, duration, whether
the AE was serious, its intensity, its relationship to the
trial drug, any action taken and clinical outcome. Sum-
mary tables present the number of subjects observed
with AEs and corresponding percentages. Additional
subcategories are based on event intensity and relation-
ship to trial drug.
Analysis of clinical laboratory findings
Listings are prepared for each laboratory measure and
structured to permit review of the data per subject as
they progress on treatment. Summary tables are pre-
pared to examine the changes of laboratory measures
over time. Additionally, shift tables are provided to
examine the changes of laboratory data from normal
baseline to values outside the corresponding reference
range during/after treatment. HCQ levels will be
assessed at the end of the study.
Discussion
Children’s interstitial lung diseases (chILD) cover a
large, heterogenic group of rare pediatric pulmonary
disorders. They are difficult to diagnose, many are
not yet genetically defined, there are no evidence-
Table 1 Definition of responders (change of oxygenation) to treatment depending on the patient’s condition
Patient’s condition Measured parameters Definition of significant change or
responder to the initiation of
hydroxychloroquine (HCQ)
Definition of significant
change or responder to
the withdrawal of HCQ
Method of aggregation
In room air SaO2
Respiratory rate
Increase ≥ 5% in O2 Sat,
or
Decrease in resp. rate≥ 20%
Decrease ≥ 5% in O2 Sat,
or
Increase in resp. rate≥ 20%
Proportion of responders
Using O2 supplement SaO2 withdrawal
Respiratory rate
Increase ≥ 5% in O2 Sat
or
Decrease in resp. rate≥ 20%
or
Support no longer needed
Decrease ≥ 5% in O2 Sat,
or




Using high-flow nasal cannula O2 flow, air flow Decrease ≥ 20%
or





Ventilated Oxygenation index Decrease ≥ 20%
or
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based pharmacological treatments and the natural dis-
ease course cannot be reliably predicted, as such in-
formation is frequently lacking. Some years ago, we
implemented a web-based international European
registry and biobank – the European Management
Platform for Children’s Interstitial Lung Diseases
(chILD EU Register) [7] to provide structures for the
collection and care of such “orphaned” patients. The
platform also has the technical and legal requirements
to perform investigator-initiated, randomized con-
trolled treatment trials. This study is embedded in
the chILD_EU Register and is the first prospective,
international, interventional study of chILD. At the
beginning of the project in 2011 we did not anticipate
the broad diversity and depth of the burdens and pit-
falls that we were facing. Here we will discuss some
decisions that we had to make from the beginning to
the successful implementation of this trial.
1. Which of the chILD entities should be included
into the study?
As the entities for which empiric treatment with HCQ
was successful were not molecularly defined, we decided
to be as inclusive as possible. Nevertheless, our inclusion
criteria were clearly set to select so far: (1) subjects of all
ages (premature infant to adults) with genetically defined
surfactant-dysfunction syndromes or molecularly defined
diseases caused by mutations in genes associated with
diffuse parenchymal lung diseases and anecdotal or pos-
sible responsiveness to HCQ; (2) mature newborn (≥ 37
weeks of gestational age) to young adults with lung biop-
sies showing any of the histopathology pattern and clin-
ical phenotypes known to be associated with these well-
defined conditions and (3) children with idiopathic
pulmonary hemosiderosis, in the absence of a lung bi-
opsy, due to some evidence for HCQ responsiveness
[12]. In an amendment, the following entities were
removed: microvasculopathy, cryptogenic organizing
pneumonia, diffuse alveolar damage/acute interstitial
pneumonia, acute fibrinous and organizing pneumonia,
giant-cell pneumonia, chILD clinically diagnosed (CDB-ILD),
respiratory bronchiolitis-interstitial lung disease, sarcoidosis,
hypersensitive pneumonitis, neuroendocrine-cell hyperplasia
of infancy and pulmonary interstitial glycogenosis. Reasons
to exclude the first six entities were that they were non-
specific and non-predicting for the diagnosis of chronic dif-
fuse parenchymal lung disease; the next three entities were
excluded as there are established and specific treatment re-
sponses in adult patients and the last two have generally a fa-
vorable natural course and lack any previous data of HCQ
responsiveness. These restrictions narrow the disease
spectrum, thus the revised collection includes either genetic-
ally well-defined entities or complementary histopathologic-
ally defined chronic diffuse parenchymal lung diseases,
previously clarified as idiopathic interstitial pneumoniae [13].
Despite some potential disadvantages associated, e.g., a great
variability of disease severity as currently known, a broad
range of different molecular entities, potentially new and dif-
ferent underlying pathomechanisms, a wide age-range from
infancy into adulthood, we expected significant advantages
to this “basket” approach. An important justification comes
from the molecular definition of the diseases, at least allow-
ing “n of 1” descriptions and later grouping of similar obser-
vations. As this Phase 2b study is exploratory, some entities
with good responses may be identified and allow later focus-
ing on these. Additionally, the approach selected here mir-
rors everyday care and clinical routine, i.e., treating the
majority of this group of chILD patients empirically, enhan-
cing their chances of participating in this study.
Table 2 Inclusion criteria for patients to participate in the study
1 Diagnosis of chronic (≥ 3 weeks duration)
diffuse parenchymal lung disease chILD:
a) Geneticallya or
b) Histologicallyb
Diagnosis of chronic (≥ 3 weeks duration)
idiopathic pulmonary hemorrhage
(hemosiderosis)
2 If chILD genetically diagnosed: patients of
all ages (including preterm babies and
adults age > 30 years)
If chILD histological diagnosed or diagnosis
of idiopathic pulmonary hemorrhage:
mature newborn (age ≥ 37 weeks of
gestation age) to adults (age ≤ 30 years)
3 Patients should be clinically stable during
baseline (between visits 1 and 2) for
inclusion into the studyc
4 START block: no HCQ treatment in the
last 12 weeks
STOP block: stable HCQ treatment for at
least the last 12 weeks
5 Ability of subject or/and legal representatives
to understand character and individual
consequences of clinical trial
6 Signed and dated informed consent of the
subject (if the subject has the ability) and the
representatives (of under-age children) must
be available before start of any specific
trial procedures
aSurfactant dysfunction disorders including patients with mutations in SFTPC,
SFTPB, ABCA3, NKX2–1, further extremely rare entities with specific mutations;
for example, in TBX4, NPC2, NPC1, NPB, COPA, LRBA and other genes
bChronic pneumonitis of infancy (CPI), desquamative interstitial pneumonia
(DIP), lipoid pneumonitis/cholesterol pneumonia, non-specific interstitial
pneumonia (NSIP), pulmonary alveolar proteinosis after the exclusion of
mutations in granulocyte-macrophage colony-stimulating factor-receptor
(GMCSF-R)a/b and GMCSF autoantibodies, usual interstitial pneumonia (UIP),
follicular bronchitis/bronchiolitis/lymphogenic interstitial pneumonia (LIP),
storage disease with primary pulmonary involvement (e.g., Niemann-Pick)
cTo determine this, attending physicians can use SpO2 in room air for patients
on room air or on O2 supplement; the absolute difference in SpO2 is expected
not to be ≥ 5% between visits 1 and 2. For patients on respiratory support, the
summary key parameters should not change ≥ 20% between visits 1 and 2
and no major changes in other medications between visits 1 and 2
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2. Can families living far away from a study center be
included?
To avoid disadvantages for families and patients living
in remote areas, we tried to open as many trial centers
as possible. However, it was soon evident that the finan-
cial and, in particular, the administrative burden was too
big and in Germany in the beginning of 2019, 12 study
centers were open. While the Ethics Committee would
allow expansion of a clinical trial site to another hospital
(“flying doctor”) to prevent excluding patients for no
good reason, the administrative office of the sponsor and
the lead clinical trial unit did not agree to this approach.
3. How can we maximize participation in the trial?
As already described above, we designed separate
START and STOP blocks, which was helpful to recruit
subjects otherwise lost because subjects were already taking
the medication. It will be interesting to analyze the results
with statistical approaches, that take care of such design
features. To our knowledge, similar approaches have not
been used widely. Due to the heterogeneity of the diseases
with a wide spectrum of clinical symptoms and severity it
is not possible to determine one specific HCQ mode of
duration that will fit the majority of subjects. Physicians an-
ticipate the treatment of some patients who will be treated
with HCQ only for some weeks as well as patients who will
need HCQ treatment for several years. Due to the variety
of clinical conditions and our intention to be as inclusive
as possible in this exploratory trial, we allowed a variable
time period in which patients were treated with HCQ be-
tween the START and STOP blocks. As this is an
investigator-initiated trial, reimbursement of the sites for
including subjects is limited and is very much dependent
on the funding organizations (DZL €4000 and E-rare
€6000 for START and STOP). Lastly, and despite more
than 50% of those known to the study centers being re-
cruited into the trial, it was soon evident that the number
of cases observed in Germany was insufficient to complete
the trial. Luckily, we could obtain an international grant,
which would allow us to start to expand the study into six
other European countries (Portugal, Spain, Austria, Poland,
Italy and Turkey). We hope that we can successfully per-
form this study and that it will generate some important
insights into the fascinating areas of chILD.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13063-020-4188-4.
Additional file 1. a. Time schedule of the HCQ START block and trial
assessments. b.Time schedule of the HCQ STOP block and trial
assessments.
Table 3 Exclusion criteria for patients to participate at the study
1. chILD primarily related to developmental disorders;
chILD primarily related to growth abnormalities
reflecting deficient alveolarizationa; chILD related
to chronic aspiration; chILD related to immunodeficiency;
chILD related to abnormalities in lung-vessel structure;
chILD related to organ transplantation/organ
rejection/GvHD; chILD related to recurrent infection
2. Acute severe infectious exacerbations
3. Known hypersensitivity to HCQ, or other ingredients
of the capsules (lactose monohydrate, povidone,
maize starch, magnesium stearate, hypromellose,
macrogol or titanium dioxide (E 171), silicon
dioxide or mannitol), to sucrose octaacetate
or sodium saccharin
4. Proven retinopathy or maculopathy
5. Glucose-6-phosphate-dehydrogenase deficiency
resulting in favism or hemolytic anemia, myasthenia
gravis, hematopoietic disorders
Pregnancy and lactation (women with childbearing
potential have to practice a medically accepted
contraception during the trial and til 3 months
after the end of the treatment with HCQ, and a
negative pregnancy test (serum or urine) should
be existent on visit 1 if they are girls of childbearing
age and only if sexual relations are known or
probable. It is at the discretion of and is the
responsibility of the attending physician to
decide whether a pregnancy test is necessary
or not. Reliable contraceptives are systematic
contraceptives (oral, implant, injection). Women
who are sterile through surgery can participate
in the trial. At the discretion of the investigator,
sexual abstinence is also accepted as a contraceptive
method. Girls after the menarche must receive
counseling about birth control methods in the
presence of at least one parent, which has to be
documented in the patient’s notes
6. Participation in other clinical trials during the present
clinical trial or not beyond the time of 4 half-lives of
the medication used, at least 1 week
7. Hereditary galactose intolerance, lactase deficiency or
glucose-galactose malabsorption
8. Renal insufficiency at screening, defined as glomerular
filtration rate (GFR)
< 40 mL/min/1.73 m2 in patients aged 3 to 8 weeks
< 60 mL/min/1.73 m2 in patients ≥ 8 weeks of age
9. Liver disease, gastrointestinal disorder, hematological
disorder, epilepsy or other neurological disorder,
psoriasis, porphyria at the discretion of the treating
physician
10. Simultaneous prescription of other potentially
nephrotoxic or hepatotoxic medication at the
discretion of the treating physician
List of abbreviations: chILD children’s interstitial lung disease, GvHD graft
versus host disease, mL milliliter, min minutes, GFR glomerular filtration rate,
HCQ hydroxychloroquine
aIf not diagnosed with a specific genetic cause (listed in Table 3)
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ABCA3: ATP-binding cassette transporter 3; chILD: Children’s interstitial lung
disease; COPA: Coatomer subunit alpha; FAF: Fundus auto-fluorescence;
GFR: Glomerular filtration rate; gGT: Gamma glutamyl transpeptidase; GMCSF-
R: Granulocyte-macrophage colony-stimulating factor-receptor;
GOT: Glutamic oxaloacetic transaminase; GPT: Glutamate pyruvate
transaminase; GvHD: Graft versus host disease; HCQ: Hydroxychloroquine;
ILD: Interstitial lung disease; ITT: Intention-to-treat; LDH: Lactate
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Homeobox 1; NP B/C: Niemann-Pick disease B/C; OCT: Ocular coherence
tomography; SAP: Statistical analysis plan; SFTPB/C: Surfactant protein B/C;
TBX4: T-box transcription factor 4
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